amarantus bioscience holding
(AMBS:OTCQB)
amarantus bioscience holding (AMBS) Snapshot
|
Open
$0.04
|
Previous Close
$0.04
|
|
|
Day High
$0.05
|
Day Low
$0.04
|
|
|
52 Week High
01/2/13 - $0.20
|
52 Week Low
09/6/12 - $0.0040
|
|
|
Market Cap
17.3M
|
Average Volume 10 Days
1.9M
|
|
|
EPS TTM
--
|
Shares Outstanding
385.0M
|
|
|
EX-Date
--
|
P/E TM
--
|
|
|
Dividend
--
|
Dividend Yield
--
|
Related News
amarantus bioscience holding (AMBS) Related Businessweek News
No Related Businessweek News Foundamarantus bioscience holding (AMBS) Details
Amarantus BioScience Holdings, Inc., a development-stage biotechnology company, focuses on the discovery and development of drug candidates and diagnostic blood tests to diagnose and treat human diseases in the United States. The company is developing the Mesencephalic-Astrocyte-derived Neurotrophic Factor, a therapeutic protein to treat Parkinson’s diseases, as well as for other apoptosis-related disorders, including ischemic heart disease, traumatic brain injury, and orphan diseases; LymPro, blood test to diagnose Alzheimer’s disease; NuroPro to diagnose neurodegenerative diseases; and BC-SeraPro to diagnose breast cancer. It also owns PhenoGuard cell lines for the screening and discovery of biologic drug candidates and biomarkers of the central nervous system. The company was formerly known as Amarantus Bioscience, Inc. and changed its name to Amarantus Bioscience Holdings, Inc. in April 2013. Amarantus Bioscience Holdings, Inc. was founded in 2008 and is based in Sunnyvale, California.
amarantus bioscience holding (AMBS) Top Compensated Officers
amarantus bioscience holding (AMBS) Key Developments
Amarantus Bioscience Holdings, Inc.’s common stock will be deleted from OTC Bulletin Board (OTCBB) effective April 26, 2013 for failure to comply with rule NASD 6530.
On April 15, 2013, Amarantus Bioscience Holdings Inc. appointed Russell Miller as Director of Investor Relations. Mr. Miller previously served as Director of Investor Relations for US Data Works and for Force Protection Inc.
Amarantus BioScience, Inc. intends to make acquisitions. The Company intends to acquire clinical-stage drug candidate to complement Mesencephalic Astrocyte Neurotrophic Factor (MANF) within its Amarantus Therapeutics subsidiary. Gerald E. Commissiong, President and Chief Executive Officer of Amarantus BioScience said: "While our near-term development objectives remain the same, the new structure will allow us to allocate capital more efficiently, and form management teams specific to each business or product line. We will also be able to create new business units to leverage other assets we already own, such as our PhenoGuard Protein Discovery platform, or that we may acquire. Additionally, we have decided not to spinoff Amarantus Diagnostics at this time, and will re-evaluate the potential spinoff of various business units as the situation with each entity unfolds."
| Recently Viewed | |||
| AMBS:US | $0.05 USD | +0.0031 |  |
| Company | Last | Change | |
| No competitor information is available for AMBS. | |||
| View Industry Companies | |||
Industry Analysis
AMBS
Industry Average
| Valuation | AMBS | Industry Range |
| Price/Earnings | -- | Not Meaningful |
| Price/Sales | -- | Not Meaningful |
| Price/Book | -- | Not Meaningful |
| Price/Cash Flow | -- | Not Meaningful |
| TEV/Sales | -- | Not Meaningful |
Post a JobJobs
- New York, NY |Posted: May 17
- San Francisco, CA | YelpPosted: May 02
- San Francisco, CA | YelpPosted: May 02
- New York, NY | New York UniversityPosted: Apr 19
Sponsored Financial Commentaries
Sponsored Links
To contact AMARANTUS BIOSCIENCE HOLDING, please visit www.amarantus.com. Company data is provided by Capital IQ. Please use this form to report any data issues.
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.
